Albany Molecular Research Inc. (AMRI), a contract research and manufacturing organization, has signed a collaboration agreement with the New York Center for Nanomedicine Research (NYCNMR) to co-market nanotechnology services to global pharmaceutical and biotechnology clients.

As part of the three-year agreement, AMRI gains access to NYCNMR’s nanoscale therapeutic and formulation services. NYCNMR’s customers will benefit from AMRI’s suite of integrated drug-discovery solutions, which includes expertise in assay method development, high-throughput screening, high-content screening, hit-to-lead-medicinal chemistry, computer-aided drug discovery and in vitro DMPK (drug, metabolism and pharmacokinetic) assays, as well as access to its proprietary ASCC (AMRI Synthetic Compound Collection) small-molecule and natural products collections.

Housed at the University at Buffalo’s Clinical and Translational Research Center on the Buffalo Niagara Medical Campus, NYCNMR is working with pharmaceutical companies, academic researchers, and corporate clients on commercialization efforts by applying nanotechnology to clinical applications.

Source: AMRI